VARIVAX DIN 02239199
Status: Cancelled Post Market
Holder: MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.
Health Canada record
| Active ingredient(s) | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BK01 VARICELLA, LIVE ATTENUATED |
| Original market date | 21-Jan-1999 |
| Current status date | 01-Aug-2001 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02240776 | VARIVAX II | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Powder For Solution | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT | Cancelled Post Market |
| 02315939 | ZOSTAVAX | MERCK CANADA INC | Powder For Suspension | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 19400 PFU | Cancelled Post Market |
| 02375516 | ZOSTAVAX II | MERCK CANADA INC | Powder For Suspension | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 19400 PFU | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 3156 | 1998-12-02 | New Drug Submission (NDS) |